乳腺癌中ABC载体蛋白介导的多药性耐药性和向策略的开发
Xiaoyun Yu1,2, Qihang Shang3, Mengrui Yang4
1College of Traditional Chinese Medicine, Shandong Second Medical University, Weifang, 261053, China.
乳腺癌 (BrCa) 中的多药耐药性 (MDR) 限制了治疗的有效性. 了解和克服MDR机制,特别是P-gp,MRP1和BCRP等ABC载体,对于改善患者的治疗结果至关重要.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 药理学 药理学是指药理学的学科.
背景情况:
- 多药耐药性 (MDR) 显著挑战乳腺癌 (BrCa) 治疗,导致疗效降低和复发率增加.
- MDR的分子机制很复杂,涉及ABC药物载体流量,药物代谢的改变和瘤微环境.
- 对ABC载体蛋白的异常表达是BrCa中MDR的关键驱动因素.
研究的目的:
- 审查P-glycoprotein (P-gp),多药耐药蛋白1 (MRP1) 和乳腺癌耐药蛋白 (BCRP) 在BrCa MDR中的作用.
- 探索影响ABC载体表达和功能的因素,包括乳腺癌干细胞 (BCSC),表观遗传变化和瘤微环境.
- 突出克服MDR的策略,如基因修饰,新药开发和细胞膜脂质调节.
主要方法:
- 专注于乳腺癌中的ABC载体 (P-gp,MRP1,BCRP) 的文献综述.
- 分析影响传递器表达和功能的因素.
- 综合目前打击MDR的战略.
主要成果:
- P-gp,MRP1和BCRP是关键的ABC传递器,与BrCa MDR有关.
- BCSCs,表观遗传变化,细胞膜脂质和微环境因素调节ABC转运体活动.
- 目前正在研究各种策略来克服MDR.
结论:
- 准ABC载体和相关因素对于提高BrCa治疗疗效至关重要.
- 涉及遗传学,药理学和脂质调节策略的多方面的方法有望解决MDR.
- 进一步研究推动MDR的因素的复杂相互作用是必要的临床进步.
更多相关视频
08:59Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down
Published on: December 11, 2017
13:19Quantifying Antibody-Dependent Cellular Cytotoxicity in a Tumor Spheroid Model: Application for Drug Discovery
Published on: April 26, 2024
相关概念视频
ABC Transporters: Exporter
Carrier-Mediated Transport
Active transport involves two types of membrane-spanning transporters: uptake and efflux. Uptake transporters are expressed in the small...
Targeted Cancer Therapies
There are several types of targeted therapies against...
ABC Transporters: Importer
In bacteria, based on the number of transmembrane helices and the chemical nature of their substrates, the ABC importers can be divided into three types:
Treatment Resistant Cancers
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
